Related Experiment Video
Updated: Jun 30, 2026

Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays
Published on: January 7, 2016
[Growth hormone usage in Prader-Willi syndrome]
1Instituto da Criança, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, SP, Brazil. durvald@iconet.com.br
Insights
Prader-Willi syndrome (PWS) is a genetic disorder causing hypotonia and later hyperphagia leading to obesity. Growth hormone therapy (hrGH) can improve PWS patient outcomes but requires careful respiratory monitoring.
Area of Science:
- Genetics
- Endocrinology
- Pediatrics
Context:
- Prader-Willi syndrome (PWS) affects 1 in 60,000, caused by loss of paternal chromosome 15.
- PWS presents with severe hypotonia in infancy, followed by hyperphagia and obesity around age four.
- This leads to life-threatening complications including inanition and alveolar hypoventilation.
Purpose:
- To investigate the role and safety of growth hormone therapy (hrGH) in Prader-Willi syndrome patients.
- To assess the impact of hrGH on body composition, physical activity, and height in PWS.
- To highlight critical safety considerations for initiating hrGH treatment in PWS.
Summary:
- hrGH treatment aims to improve body composition and physical activity in PWS patients.
- Many PWS individuals have growth hormone deficiency, and hrGH can improve height standard deviation scores.
- Initiating hrGH requires mandatory evaluation of sleep apnea and airway examination due to potential respiratory compromise.
Impact:
- Optimizing hrGH therapy can enhance quality of life for individuals with Prader-Willi syndrome.
- Early identification of growth hormone deficiency and appropriate treatment can mitigate PWS-related growth issues.
- Vigilant respiratory monitoring during hrGH treatment is crucial for patient safety and preventing adverse events.
Abstract:
Prader-Willi syndrome (PWS), with a prevalence of 60:1.000.000, results from the loss of paternal chromosome 15, being 56% due to deletion, 24% due to uniparental maternal disomy, and 18% from methylation, an epigenetic phenomenon. The clinical picture begins with extreme muscular hypotonia, which makes it difficult to feed the child in the first year. As the hypotonia improves, usually in the first two years, around the 4th year of life, an insatiable appetite leads these children to an extreme obesity, with alveolar hypoventilation which endangers their lives. So, paradoxically, PWS threatens the lives of the patients, through inanition in a first phase and, afterwards, through excessive weight gain. The use of growth hormone (hrGH) in these children has a primary goal to change the body composition and improve the physical activity and the quality of life. On the other hand, many PWS patients are indeed GH deficient, and an improvement in the height SDS occurs with treatment. We have to be careful, however. When starting a PWS treatment with a patient on hrGH, a careful evaluation of sleep apnoea (polysomnography) as well as a careful examination of the airways is extremely mandatory, since the treatment may compromise the respiratory pattern of some patients.
Related Concept Videos
Hypoglycemia and Glucagon
Major Hormones and Their Functions
Oxytocin, produced in the hypothalamus and released by the pituitary gland, plays a role in social bonding, childbirth, and lactation.
Cellular Adaptation II: Hypertrophy
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Nature and Nurture
Cellular Adaptation III: Hyperplasia
